Precigen stock jumps 77% after FDA approves PAPZIMEOS, the first therapy targeting adult recurrent respiratory papillomatosis ...

Ethereum gains quietly while Bitcoin hype fades—analysts see stronger short-term potential for ETH as sentiment shifts.

Fintel reports that on August 15, 2025, JP Morgan upgraded their outlook for Precigen (NasdaqGS:PGEN) from Underweight to ...

Shares in biopharmaceutical company Precigen (PGEN) rocketed higher today after the U.S. Food and Drug Administration gave ...

The U.S. FDA has given a swift and full approval to Precigen Inc.’s gene therapy, Papzimeos (zopapogene imadenovec), for treating adults with recurrent respiratory papillomatosis (RRP), a rare and ...

This first approved medical therapy for RRP generates an immune response against the causative HPV strains. It uses ...

Earlier today, it was announced that Precigen’s PAPZIMEOS (formerly PRGN-2012) was FDA-approved for adults with RRP. Read why ...

Papzimeos is the first and only FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP), with ...

Zopapogene imadenovec is a non-replicating adenoviral vector-based immunotherapy designed to induce an immune response against HPV 6 and HPV 11 proteins.

The FDA approved the adenoviral vector-based immunotherapy, zopapogene imadenovec-drba, for treatment of certain patients ...

The US Food and Drug Administration (FDA) has approved Papzimeos (zopapogene imadenovec-drba) for the treatment of adults ...

Papzimeos, the first-ever treatment approved for RRP is a moment for celebration and reflection FORT WORTH, Texas, August 15, 2025--(BUSINESS WIRE)--The Recurrent Respiratory Papillomatosis Foundation ...